TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01548768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF inhibitors
Description: TNF inhibitors are an FDA approved class of medications indicated for the treatment of RA when initial treatment (usually with methotrexate) has failed to achieve remission of RA disease activity. TNF inhibitors are part of the standard of care management of RA.~The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMARDs
Description: Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.
Study: NCT06336187

Intervention type: GENETIC
Intervention: molecular investigation
Description: Transcriptomic analysis of tissues
Study: NCT04454034

Intervention type: PROCEDURE
Intervention: arthroscopic synovectomy
Description: arthroscopic synovectomy
Study: NCT04268537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody+standard treatment
Description: After randomization, PD-1 blocking antibody 200mg iv, one time. Standard treatment is according to the protocol of treatment of 2019-nCoV infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin+standard treatment
Description: Thymosin 1.6 mg sc qd, last for 5 days. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study: NCT02806271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Worry Postponement
Description: In worry postponement, participants are instructed to learn to notice naturally occurring episodes of worry. When they notice they are worrying they are instructed to disengage from their worry and postpone it to a designated 30 minute worry period to be carried out at the same time and place daily during the two week intervention. Participants are to use their worry time to worry about problems that have come up during the day and to problem solve where appropriate.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Worry Monitoring
Description: For two weeks participants are instructed to monitor their worry using a smartphone based application. Participants are instructed to make a record each time they have a worry episode by briefly describing the content of their worry. Participants also complete two brief daily questionnaires about the duration of their worry, the intensity of their worry, their ability to disengage from their worry, and the occurrence of nighttime episodes of worry.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Worry Monitoring
Description: For two weeks participants are instructed to monitor their worry using a smartphone based application. Participants are instructed to make a record each time they have a worry episode by briefly describing the content of their worry. Participants also complete two brief daily questionnaires about the duration of their worry, the intensity of their worry, their ability to disengage from their worry, and the occurrence of nighttime episodes of worry.
Study: NCT04070248

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04268537

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard treatment
Description: Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study: NCT04539483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDIT101 (blinded therapy)
Description: Patients will be treated with with topical HDIT101 (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (blinded therapy)
Description: Patients will be treated with with topical placebo (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo documentation of orolabial herpes lesions
Description: Patients will be asked to document their orolabial lesions with photos by using their smart phone

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Photo documentation of orolabial herpes lesions
Description: Patients will be asked to document their orolabial lesions with photos by using their smart phone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Completion of questionnaires (patient-reported outcomes)
Description: Patients will be asked to document their health status in questionnaires by using their smart phone

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Completion of questionnaires (patient-reported outcomes)
Description: Patients will be asked to document their health status in questionnaires by using their smart phone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 28-day swabbing of orolabial region
Description: Patients will be asked to complete 3 episodes of 28-day swabbing of orolabial lesions

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 28-day swabbing of orolabial region
Description: Patients will be asked to complete 3 episodes of 28-day swabbing of orolabial lesions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood drawings
Description: Blood will be drawn for e.g. safety lab, HSV-analysis, pharmacokinetic etc.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood drawings
Description: Blood will be drawn for e.g. safety lab, HSV-analysis, pharmacokinetic etc.
Study: NCT03752086

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: greater omentum binding
Description: Bind pancreatic stump using greater omentum after distal pancreatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic stump exposed without omentum binding
Description: Pancreatic stump exposed without greater omentum binding after distal pancreatectomy
Study: NCT04070248

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04028323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Terlipressin should be administrated intravenously while monitoring heart rate and blood pressure daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Octreotide should be continuously intravenously administrated while monitoring heart rate and blood pressure daily.
Study: NCT02290119

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensor-assisted TKR (Verasense)
Description: Verasense is a single use, disposable device embedded with microelectronics into a standard tibial trial to provide dynamic, intraoperative feedback regarding limb alignment, tibiofemoral position and quantitative pressure at peak contact points in the medial and lateral compartments during total knee replacement surgery. Utilizing sensor-derived data, the surgeon can now evaluate intercompartmental loading throughout the range of motion, and correct for soft-tissue abnormalities while receiving real-time feedback regarding joint balance.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control - Without the use of Verasense
Description: Patients in this cohort will undergo manual total knee replacement without the use of Verasense
Study: NCT00985933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8529
Description: 6 capsules by mouth 1 time 12 to 24 prior to assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8529
Description: 6 capsules by mouth 1 time 12 to 24 prior to assessments

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD8529
Description: 6 capsules by mouth 1 time 12 to 24 prior to assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match AZD8529
Description: 6 capsules by mouth 1 time 12 to 24 hours prior to assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match AZD8529
Description: 6 capsules by mouth 1 time 12 to 24 hours prior to assessments

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match AZD8529
Description: 6 capsules by mouth 1 time 12 to 24 hours prior to assessments
Study: NCT03699371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Supplemental Parenteral Nutrition
Description: Intervention group: would receive EN reaching up to 20 % of daily nutritional requirements and early (on first day of stay in ICU) provision (of up to 80%) of protein (2 g/kg/ day or in case of CRRT 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day) needs in SPN that would be continued until 7th day of stay in ICU. Central venous catheter placement would not be assessed as a part of intervention due to the fact that it is a part of routine medical activities performed during admission to ICU.
Study: NCT04039425

Intervention type: PROCEDURE
Intervention: Hair cut
Description: Use only head hair. Cut samples of hair from back of head (see illustration). Cut hair as close to the scalp as possible. As each piece of hair is cut from the head, save only 3.7 square inches of hair closest to the scalp. According to the Doctors Data Lab, this amount is about enough hair to fill a tablespoon. Cut off and discard the rest. Place the saved hair on the scale. Keep cutting and adding hair to the scale until it tips. Hair collection will be about the weight of one to two paper clips (about 3800 strands). Remove the hair on the scale and put it in the plastic bag. Label the plastic bag with the patient's unique random identification and the date collected. Put the hair into the plastic bag, seal, and send to The Doctor's Data Lab.
Study: NCT00857467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 1 g rectal suppository, with a 7-day washout period between dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository, with a 7-day washout period between dosing.
Study: NCT03309228

Intervention type: OTHER
Intervention: individual interviews
Description: Semi-structured individual interviews with patients, relatives and general practitioners.
Study: NCT01786031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: metastasis biopsy
Study: NCT01773018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volitinib
Description: Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mgand 200 mg,oral,once daily.
Study: NCT06124651

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement with cruciate retaining femoral component
Description: To perform the total knee replacement, the knee joint is anatomically dissected, and thin portions of bone and cartilage is resected to accommodate a metallic implants. Implants are fixed to patients' bone with bone cements. Many designs for femoral component designs are available. In the present study, two types of implants, one CR(cruciate retaining), where the posterior cruciate ligaments are retained, and one PS(Posterior cruciate substituting), where the posterior cruciate ligaments are resected, will be compared. To make the comparison more reliable, the same kind of implants will be used, so that the major portions of femoral component design remains the same and the tibial component remains the same. Only the cruciate ligament parts are different. For this arm of intervention, CR knee will be used, so posterior cruciate will remain intact after the surgery and still function to aid in the knee stability.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement with cruciate substituting femoral component
Description: To perform the total knee replacement, the knee joint is anatomically dissected, and thin portions of bone and cartilage is resected to accommodate metallic implants that has similar contours of a native knee. Implants are fixed to patients' bone with bone cements. This procedure will use the femoral component that sacrifice the posterior cruciate ligament and having a box area with a post, so that cam-post mechanism of implants can mimic the function of the posterior cruciate ligament. To make the comparison more reliable, the same kind of implants will be used, so that the major portions of femoral component remains the same. The tibial component will remain the same design. Therefore, only the cruciate ligament parts will be different.
Study: NCT04330222

Intervention type: DIAGNOSTIC_TEST
Intervention: 7 Tesla Magnetic Resonance Imaging
Description: Diagnostic Imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: 7 Tesla Magnetic Resonance Imaging
Description: Diagnostic Imaging

Intervention type: OTHER
Intervention: Brief Memory and Executive Test
Description: Cognitive Assessment
Study: NCT00619372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKT3
Description: 0.2 mg OKT3, PO (in the mouth) on day 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKT3, GC
Description: 0.2 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKT3
Description: 1 mg OKT3, PO (in the mouth) on day 1 through 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKT3, GC
Description: 1 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKT3
Description: 5 mg OKT3, PO (in the mouth) on day 1 through 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC
Description: 7.5 mg GC, PO (in the mouth) on day 1 through 5
Study: NCT02474134

Intervention type: DRUG
Group type: OTHER
Intervention: Interferon beta-1b (PF530, Betaferon)
Description: Single subcutaneous administration

Intervention type: DRUG
Group type: OTHER
Intervention: Interferon beta-1b (PF530, Betaferon)
Description: Single subcutaneous administration
Study: NCT02711020

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Patients assigned to this arm will receive a maximum of 18 1-hour sessions of Cognitive Behavioral Therapy following the intervention techniques included in various group therapy manuals for patients with fibromyalgia, plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. Techniques are adapted to individual format in the following modules: (1) Psychoeducation, (2) Relaxation, (3) Behavioral Activation, (4) Cognitive Restructuring, (5) Problem solving, (6) Assertiveness Training, and (7) Relapse Prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Construct Therapy
Description: Patients will receive a maximum of 18 1-hour sessions of Personal Constructs Therapy plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. The intervention will follow a protocol designed specifically for this project based on the clinical experience of a previous pilot study. It will consist of 4 stages: (1) Analysis of patient's request, goals setting, identification of the main dilemmas, and other personal meanings relevant for self and others' construction; (2) feedback on the assessment results and problem reframing in terms of a dilemma and/or other personal meanings; (3) work on the dilemmas and/or other aspects of the self and others' construction; and (4) end of the therapeutic process outlining personal projects and future perspectives.
Study: NCT00660595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Oral administration
Study: NCT03594955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR440234
Description: Pharmaceutical form:lyophilisate to be resuspended in solution Route of administration: intravenous
Study: NCT03302507

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BESS
Description: Biportal endoscopic surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ULBD
Description: Unilateral laminotomy bilateral decompression
Study: NCT03580395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500mg, day1-21,neoadjuvant therapy

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel 165mg/m2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 165mg/m2 day 1
Study: NCT04629456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromuscular electric stimulation
Description: A total of eight electrodes were placed on the quadriceps femoris muscles (four on each leg): two on the vastus medialis, one on the rectus femoris muscle, and one on the vastus lateralis muscle. The stimulation protocol of the NMES consisted of a symmetrical biphasic square pulse at 75 Hz, a duty cycle of 6 seconds (sec.) on and 29 sec. off, a pulse time of 410 sec. during a session lasting 20 min. The intensity was increased to maximum individual toleration. The muscle contractions were visible and palpable.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: The chair-seated exercises were used in the early stages of the program because the participants were frail adults. Repetitions of toe raises, heel raises, knee lifts, knee extensions, and others were performed while seated on a chair. Hip flexions, lateral leg raises, and repetitions of other exercises were performed standing upright behind the chair and holding the back of the chair for stability. To strengthen lower extremities, a fixed weight was placed on the ankle while participants performed strengthening exercises. Weights of 0.50, 0.75, 1.00, and 1.50 kg were used in accordance with each participant's strength level as the resistance progressively increased. The exercises performed using these ankle weights included seated knee flexion and extension and standing knee flexion and extensions. Exercises using a resistance band: Resistance bands were used to strengthen lower body. Lower body exercises included leg extension and hip flexion
Study: NCT03580395

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: cisplatin
Description: cisplatin 40mg, day 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin 40mg, day 1-3
Study: NCT03049423

Intervention type: DEVICE
Intervention: MRI scans
Description: 30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scans and general physical examination
Description: 30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
Study: NCT02446535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: achievement of the DW by means of the BIA DW (RE.S.T.)
Study: NCT01443923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boceprevir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boceprevir
Study: NCT00615147

Intervention type: PROCEDURE
Intervention: CT pulmonary angiogram and d-dimer draw
Description: A CT pulmonary angiogram and a d-dimer drawn within 24 hours.
Study: NCT04767971

Intervention type: DEVICE
Intervention: Standard Colonoscopy
Description: Colonoscopy with a standard colonoscope

Intervention type: DEVICE
Intervention: G-EYE Colonoscopy
Description: Colonoscopy with a G-EYE Colonoscope
Study: NCT01148459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biological's Investigational Malaria Vaccine 257049
Description: All infants enrolled to group A will receive 3 doses of the experimental vaccine. The vaccine will be administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);
Description: To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).
Description: To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly.
Study: NCT03675971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabinol
Description: Postoperative pain treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo comparator
Study: NCT04565405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detergent
Description: The tracheostomy inner cannulas will be washed with detergent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detergent
Description: The tracheostomy inner cannulas will be washed with detergent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile water
Description: The tracheostomy inner cannulas will be washed with sterile water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile water
Description: The tracheostomy inner cannulas will be washed with sterile water.
Study: NCT00402623

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: quercetin
Description: 1000 mg quercetin within 24 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02008032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stationary Breast Tomosynthesis
Description: The patient will have the SDBT study performed in a similar manner as conventional mammography in the mediolateral oblique and cranio-caudal plane. The participant will stand up and the mammography research technologist, ensuring patient comfort, will assist in positioning their breast in the breast tomosynthesis unit with standard compression. Once positioned, the total scan time is approximately 10 seconds. Both the left and right breast will be imaged. The length of time for the positioning and examination of a subject's breast may vary but it is expected that the entire imaging procedure will take about 5-10 min, including positioning time.